What is the value of authorised generic agreements? Assessments on the French market

Journal of Generic Medicines

Volumn 4, Issue 2, 2007, Pages 106-116

  Peny, Jean Michel ^a   Covilard, Jean Pierre ^a  

^a NONE

Author keywords

Authorised generics; Early entry strategy; Exclusivity period; Generic defence strategies; Generic market potential; Partnerships

Indexed keywords

ACICLOVIR; AMOXICILLIN PLUS CLAVULANIC ACID; CLAVULANIC ACID; FLUOXETINE; GENERIC DRUG; OMEPRAZOLE; PAROXETINE; SIMVASTATIN; ZOLPIDEM TARTRATE;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; COMMERCIAL PHENOMENA; COST BENEFIT ANALYSIS; COST CONTROL; DRUG COMPETITION; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; DRUG LEGISLATION; DRUG MARKETING; EXPIRATION DATE; FRANCE; LAW SUIT; LEGAL ASPECT; LICENSING; PATENT; PRESCRIPTION; PROFIT;

EID: 33846844919     PISSN: 17411343     EISSN: 17417090     Source Type: Journal    
DOI: 10.1057/palgrave.jgm.4950061     Document Type: Article

References (4)

1. Peny, J. M. & Covilard, J. P. (2005). The end of the back-up brands? Scrip Mag. 10, 21-25.
2. Peny, J. M. & Young, R. (1996). Are generic defence strategies worth the effort? Scrip Mag. 6, 28-34.
3. Karwal,V. (2006).The changing competitive landscape in the global generics market: Threat or opportunity? J. Gen. Med. 3(4), 269-279.
4. Peny, J. M. (2005). Barriers to substitution. Scrip Mag. 4, 19-23.